This page is intended for journalists only. Non-journalists are excluded from the intended audience

Virtual Press Office

Our ESMO Press Releases

ESMO 2020: Cabometyx® (cabozantinib) in combination with Opdivo® (nivolumab) demonstrates significant survival benefits in patients with advanced renal cell carcinoma in pivotal Phase III CheckMate -9ER trial

Read more

ESMO 2020: Phase II CLARINET FORTE results show increasing dose frequencies of Somatuline® Autogel® (lanreotide) allows patients with NETs to delay treatment escalation by up to 8.3 months

Read more

Ipsen showcases commitment to patient-centric advances in oncology with record number of abstracts to be presented at ESMO 2020 Virtual Congress

Read more

By clicking either of the above links you will be leaving the website

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved. - 2020

This page is intended for journalists only

Please confirm below that you are a journalist



I am a journalist

I am not a journalist